Medicine and Dentistry
Antiretroviral Therapy
100%
Combination Therapy
16%
Drug Resistance
50%
Efavirenz Plus Lamivudine Plus Zidovudine
16%
Epidemic
16%
Gene
16%
Human Immunodeficiency Virus
100%
Human Immunodeficiency Virus Type 1 Subtype B
33%
Inpatient
33%
Lamivudine Plus Nevirapine Plus Zidovudine
16%
Patient
100%
Plasma
16%
Proteinase
16%
Resistance Mutation
50%
Reverse-Transcriptase Inhibitor
16%
RNA
16%
RNA Directed DNA Polymerase
16%
Sequence Analysis
16%
Stavudine
16%
Tenofovir
16%
Therapeutic Procedure
16%
INIS
drugs
30%
failures
10%
genes
10%
hiv
100%
mutations
100%
nigeria
100%
nucleosides
10%
patients
100%
plasma
10%
rna
10%
sequence analysis
10%
therapy
100%
Immunology and Microbiology
Blood Plasma
10%
Drug Resistance
30%
Gene
10%
Human Immunodeficiency Virus
100%
Human Immunodeficiency Virus 1
30%
Human Immunodeficiency Virus Type 1 Subtype B
20%
Mutation
100%
Reverse Transcriptase
20%
Sequence Analysis
10%
Tenofovir
10%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Resistance
50%
Efavirenz Plus Lamivudine Plus Zidovudine
16%
Epidemic
16%
HIV
100%
Human Immunodeficiency Virus Type 1 Subtype B
33%
Lamivudine Plus Nevirapine Plus Zidovudine
16%
Proteinase
16%
RNA
16%
RNA Directed DNA Polymerase
16%
RNA Directed DNA Polymerase Inhibitor
16%
Stavudine
16%
Tenofovir
16%
Neuroscience
Antiretroviral Drugs
12%
Drug Resistance
37%
Efavirenz
12%
Gene
12%
HIV
100%
Lamivudine/Zidovudine
12%
Nevirapine
12%
Nucleoside
12%
Proteinase
12%
Reverse Transcriptase
12%
Reverse Transcriptase Inhibitors
12%
RNA
12%
Stavudine
12%
Tenofovir
12%